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ABSTRACT
Objectives: To investigate the long-term cost-
effectiveness (measured as the ratio of incremental
NHS cost to incremental quality-adjusted life years) of
a telehealth intervention for patients with raised
cardiovascular disease (CVD) risk.
Design: A cohort simulation model developed as part
of the economic evaluation conducted alongside the
Healthlines randomised controlled trial.
Setting: Patients recruited through primary care, and
intervention delivered via telehealth service.
Participants: Participants with a 10-year CVD risk
≥20%, as measured by the QRISK2 algorithm, and
with at least 1 modifiable risk factor, individually
randomised from 42 general practices in England.
Intervention: A telehealth service delivered over a 12-
month period. The intervention involved a series of
responsive, theory-led encounters between patients
and trained health information advisors who provided
access to information resources and supported
medication adherence and coordination of care.
Primary and secondary outcome measures:
Cost-effectiveness measured by net monetary benefit
over the simulated lifetime of trial participants from a
UK National Health Service perspective.
Results: The probability that the intervention was cost-
effective depended on the duration of the effect of the
intervention. The intervention was cost-effective with
high probability if effects persisted over the lifetime of
intervention recipients. The probability of cost-
effectiveness was lower for shorter durations of effect.
Conclusions: The intervention was likely to be cost-
effective under a lifetime perspective.
Trial registration number: ISRCTN27508731;
Results.
INTRODUCTION
Cardiovascular disease (CVD) is a prevalent
long-term condition associated with substantial
morbidity and mortality.1 Effective care for
patients with raised CVD risk requires atten-
tion to, and management of, underlying risk
factors such as high blood pressure (BP) and
obesity.2 A challenge in estimating the cost-
effectiveness of interventions intended to
reduce CVD risk is that randomised controlled
trials (RCTs) may have follow-up periods that
are shorter than the period over which an
intervention may affect CVD risk. This is in
spite of the impact that interventions to
reduce CVD risk—such as BP management
and weight management programmes—might
have in reducing the future occurrence of
debilitating events such as acute myocardial
infarction (AMI) and stroke.
Telehealth is one form of condition man-
agement that may be relevant to long-term
conditions in general and to CVD in particu-
lar.3 However, there is a lack of high-quality
evidence regarding the cost-effectiveness of
Strengths and limitations of this study
▪ The Healthlines trial was one of the largest ran-
domised controlled trials designed to evaluate a
telehealth-based complex intervention for the
management of cardiovascular disease risk.
▪ This study complements and extends the find-
ings of a within-trial evaluation carried out on
outcomes at 12 months from randomisation by
evaluating the cost-effectiveness of the telehealth
intervention over the lifetime of trial participants
using a cohort simulation model.
▪ The intervention is likely to be cost-effective
from a health system perspective, but we cannot
identify the most plausible duration of interven-
tion effect.
Dixon P, et al. BMJ Open 2016;6:e012355. doi:10.1136/bmjopen-2016-012355 1
Open Access Research
group.bmj.com on October 21, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
telehealth.4–7 To estimate the clinical and cost-
effectiveness of a de novo telehealth intervention, the
Healthlines CVD risk RCT individually randomised 641
participants to receive either usual care or a theory-
based telehealth intervention that encouraged partici-
pants to engage in beneﬁcial behaviour change. The
primary clinical outcome of the trial was 10-year CVD
risk, measured using the QRISK2 risk prediction algo-
rithm8 at the end of 12 months of follow-up.
In the absence of data from long-term follow-up, there
is no means of assessing the enduring impact on cost-
effectiveness of the changes in modiﬁable risk factors
that the intervention may have wrought. For example, it
is plausible that some patients who managed to reduce
their BP, body mass index (BMI) or whose medication
adherence was improved as a result of the intervention
may continue with newly acquired beneﬁcial behaviours
after the end of the 12 months of trial follow-up.
Indeed, it is implausible that all trial participants would
immediately revert to their preintervention BP or BMI
immediately on trial completion.
This paper describes the development and analysis of
a state transition cohort simulation cost-effectiveness
model intended to estimate the expected net beneﬁts of
the Healthlines telehealth intervention over the lifetime
of trial participants. This approach is consistent with the
principles of economic evaluation,9 guidance from the
National Institute for Health and Care Excellence
(NICE)10 and ISPOR guidelines11 which recommend
that cost-effectiveness analyses be undertaken over a
time period that reﬂects differences in cost and effect
attributable to an intervention or treatment. The long-
term cost-effectiveness analysis complements the analysis
of cost-effectiveness of the intervention at 12 months
postrandomisation published in a companion paper.12
The Healthlines RCT
The trial protocol, methods, results and cost-
effectiveness analyses have been reported elsewhere.3 13
Brieﬂy, patients aged between 40 and 74 with 10-year
CVD risk ≥20% (measured by the QRISK2 algorithm)
and at least one modiﬁable risk factor (eg, weight man-
agement or smoking) were recruited from 42 GP prac-
tices in England. Individuals were not considered if they
had a conﬁrmed diagnosis of CVD, were pregnant, did
not have access to the internet and telephones or were
unable to communicate verbally. More detail on these
and other exclusion criteria is available in Salisbury
et al.3 In total, 641 patients were randomised, and
received either unmodiﬁed usual care (n=316) or a tele-
health intervention in addition to usual care (n=325),
for a follow-up period of 12 months.
Participants in the intervention arm could receive up
to 13 responsive, tailored telehealth encounters with
trained Health Information Advisors. Participants were
encouraged to access and use online material and apps
related to CVD risk. Participants with systolic BP
≥140 mm Hg and without atrial ﬁbrillation were offered
a BP monitor to use at home, and could upload read-
ings to a portal to monitor progress. Telephone calls
focused on goal setting, stimulus control and the man-
agement of CVD risk in a way that was relevant to the
circumstances of each individual participant and which
was in line with NICE guidelines. This included ensuring
that patients were taking appropriate drug treatment,
and addressing problems with medication adherence.
The within-trial economic evaluation at the end of
12 months of follow-up adopted an NHS perspective. The
cost-effectiveness of the intervention was estimated against
NICE thresholds using NHS cost data collected from
medical records and questionnaires during the trial, and
using data on quality-adjusted life years (QALYs) estimated
from responses to the EQ-5D-5L14 generic quality-of-life
measure at baseline, and 6 and 12 months from random-
isation. The mean incremental NHS costs in 2012/2013
prices were estimated to be £138 per patient (ie, the inter-
vention was more expensive), and the mean incremental
QALY gains were estimated to be 0.012. The estimated
ICER was £10 859, and the estimated net beneﬁt at a
threshold of £20 000 was estimated to be £116 (95% CI: −
£58 to £291). The probability that the intervention was
cost-effective at this threshold value was 0.77.
METHODS
Model structure
Cohorts of 1000 patients were simulated. These cohorts
were based on the characteristics of the 641 trial partici-
pants. Cohorts differed according to age at randomisa-
tion, sex and trial allocation of the patient groups
modelled. A set of discrete, mutually exclusive states
were created and deﬁned by the presence (or absence)
of a CVD-related condition, or with death (ﬁgure 1).
Sequences of states experienced by the simulated cohort
members deﬁned clinical pathways in which QALYs
(associated with utilities and mortality) and costs were
accumulated. Cost-effectiveness, as measured by the
averages of costs and QALYs in each arm, was the
primary outcome. These averages were calculated and
allowed for the construction of net beneﬁt statistics.
Costs were expressed in 2012/2013 sterling prices.
The model is based on adapted updated versions of
models used in previous health technology assessments in
the area of CVD risk.15 16 A National Health System per-
spective was adopted. The model cycled annually. Costs
and outcomes were subject to a half-cycle correction.17
Consistent with the inclusion criteria of the trial, and the
construction of the QRISK2 algorithm,8 patients were
assumed to be free of CVD when they entered the model
—this corresponds to the ‘event free’ state. Subsequent
states correspond to the occurrence of the events used in
the QRISK2 algorithm—AMI, angina, transient ischaemic
attack (TIA) and stroke—and to postevent states, for
example, a ‘poststroke’ state (ﬁgure 1).
Patients cycled through the model until death, or age
100, at which point they were assumed to die. A total of
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1000 iterations of the model were simulated, in which
values of input parameters were varied simultaneously.
Each iteration used a value drawn from probability distri-
butions assigned to particular input parameters of the
model as described below, in the online supplementary
table A2 and in Salisbury et al.3 Probabilistic sensitivity
analysis was used to quantify uncertainty around point
estimates of net beneﬁt. The model was implemented in
Excel 2013 (Microsoft, Redmond, Washington, USA).
Probability of transitioning to primary and secondary
states
The probability of entering a particular state is determined
by CVD risk. Initial risk scores of patients at the beginning
of the model, corresponding to the event-free state, were
based on information collected in the RCT (table 1). CVD
risk in the initial year (year 0) is thus average participant
baseline QRISK2 score. Change in CVD risk at the end of
this year/start of the next year (year 1) is measured by
QRISK2 score calculated at 12-month follow-up and
adjusted for baseline risk, details of which are provided in
Salisbury et al.3 CVD risk in subsequent years was obtained
by adding percentage increases obtained from growth
rates in annual risk in males when all input values to the
QRISK2 algorithm other than age were held constant.
Growth rates from men were used because the level of
CVD risk is higher for men than for women at all ages,
other variables being constant. Using the relatively more
Figure 1 Simulated model
states. This figure is based on
Figure 27 of Ward et al.24
Table 1 QRISK2 scores at baseline and after 12 months of follow-up
Control arm Intervention arm
Baseline
12-month follow-up,
adjusted for baseline Baseline
12-month follow-up,
adjusted for baseline
QRISK2 score for males 31.59 32.00 31.83 31.60
QRISK2 score for females 27.73 28.24 27.86 27.84
The data are presented as levels of QRISK2 as it is the level of risk that determines the probability of events such as stroke or acute
myocardial infarction.
These data are based on imputed QRISK2 scores—multiply imputed data are used in the base case economic evaluation at 12 months from
randomisation.3 These data are based on CVD risk of all of those randomised (n=641) in the RCT. The methods used for multiple imputation
are described in further detail in the companion 12-month economic evaluation paper.12
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rapid growth rates observed in female risk levels as a
basis for extrapolation would have meant that at some
ages, female risk was much higher than male risk. The
use of male risk growth rates constrains female risk
levels to be below male levels at all ages, ensures that
risk does not rise above 100%, better reﬂects estimated
prevalence of risk in males and females, and more gen-
erally ensures that the cost-effectiveness results are based
on plausible risk proﬁles.3
The QRISK2 algorithm is not validated for ages
beyond 84. Risk for patients surviving to 85 and above
was obtained by extrapolating 10-year risk by 1% per
annum, which corresponds to the coefﬁcient obtained
from an ordinary least squares regression of QRISK2
scores on age.
Ten-year risk scores were converted into an annual risk
of any event to reﬂect the annual cycles of the model.
Annual risk scores of any deﬁned CVD event were then
disaggregated into the risk of a speciﬁc event—AMI,
angina, TIA and stroke—using data on the incidence of
these conditions by age and sex. The sources for these
data and the input values used are described in the
online supplementary tables A5 and A6. Further detail
on their calculation is available in Salisbury et al.3
These incidence rates establish the probability of
moving from the event-free state to a speciﬁc
CVD-related event state; that is, they establish the risk of a
primary event. Transitions to secondary events (any event
after the primary event) are determined by the age and
sex-speciﬁc transition probabilities given in Ara et al,15
who describe in detail the data sources and methods
used in their construction. Permitted transitions between
states are listed in the online supplementary table A1.
The probability of death due to causes not related to
CVD risk was based on standardised mortality ratios cal-
culated from the most recently available (2012) Ofﬁce
of National Statistics Interim Life Tables.18 This mortality
ratio excluded CVD-related ICD-10 codes (I20–I25 and
I60–I69). The risks of mortality used in each iteration of
the model were based on draws from a univariate
normal distribution.
Simulated participants were constrained to experience
no more than three CVD events, an assumption that
reﬂected data availability and model tractability. The same
assumption was used in Ara et al.15 However, few of the
1000 simulated participants approached experiencing
three events, and therefore, the assumption is unlikely to
have inﬂuenced cost-effectiveness conclusions.
Duration of effect of intervention
The duration of the effect of the Healthlines interven-
tion on CVD risk beyond the end of trial follow-up is
unknown, but the modelling thereof is the principal
motivation for undertaking the simulation modelling
described here. Four different scenarios based on differ-
ent durations of effect were modelled, and their implica-
tions for cost-effectiveness compared. This is similar to
the approach of Mistry et al.19
The scenarios modelled are of durations of interven-
tion effect of 1, 2 and 5 years from baseline, and for
remaining lifetime. If, for example, the duration effect is
2 years, then participants in the intervention arm receive
the beneﬁt of lower risk for 2 years, after which they are
modelled as having the same sex- and age-adjusted risk
as participants in the control arm. Similar logic applies
to the other scenarios. In the case of a lifetime duration
of effect, risk is permanently lower in the intervention
arm. To avoid sudden ‘jumps’ in risk at the point at
which the intervention ends, the model uses a smooth-
ing adjustment which calculates the average score of
intervention arm risk and usual care risk for the year
after which the modelled duration of effect expires.
Data on utility
QALYs in year 0 of the model were obtained from par-
ticipant responses to the EQ-5D-5L measure at baseline,
6 and 12 months of RCT follow-up and were ‘cross-
walked’ to UK EQ-5D-3L instrument and valued using
the Euroqol UK value set.20 QALYs were adjusted to
account for between-arm differences observed at the
end of trial follow-up. For other years of the model, age-
and sex-adjusted population, EQ-5D norms were esti-
mated from Ara and Brazier21 to provide baseline utility
scores that applied to the event-free state. These EQ-5D
data were used to calculate QALYs.
Multiplicative adjustments, which assume a constant
proportional effect on baseline utility,21 were made to
reﬂect the decremental impact of experiencing
CVD-related health states. Ara and Brazier21 was used as
the source of state-speciﬁc utilities other than TIA,
which were drawn from Luengo-Fernandez et al,22 and
for unstable angina. It was assumed that the utility esti-
mates for angina in Ara and Brazier related to stable
angina; it was further assumed that utility associated with
the unstable angina health state would be 90% of the
stable angina values, as in Ara et al.15
Condition-speciﬁc utility values were drawn from uni-
variate normal distributions, as recommended by Ara
and Wailoo,23 to reﬂect uncertainty in mean values.
Utilities corresponding to postevent states were never
lower than for the event state itself. This means, for
example, that utilities of the ‘poststroke’ event state were
higher than or equal to the ‘stroke’ state, implying that
experiencing a stroke had a greater negative impact on
average on patient utility than did experiencing the
‘poststroke’ state.
It was assumed that the second and third events (such
as second and third non-fatal strokes) had the same
impact on utility as the ﬁrst event. This rules out multi-
plicative impacts of events on quality of life. The utility
values associated with different states are presented in
the online supplementary material table A3.
Data on cost
A health-system perspective was adopted for the analysis,
and hence only NHS costs were considered. This
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excluded consideration of any personal or societal costs
associated with, for example, incapacity and exit from
the labour force connected with a debilitating but non-
fatal stroke.
The costs of health states were based, in most cases, on
Ward et al24 and Ara et al.15 The ﬁrst year of the model
also included costs of the intervention, and NHS costs
incurred in each arm. The costs of each health state are
described in the online supplementary table A4.
The cost estimates in Ward et al24 and Ara et al,15
derived from systematic reviews, were updated where
appropriate and possible with new data, as described in
more detail in Salisbury et al.3 Mean costs enter the
simulation model at each iteration as draws from a γ
distribution.
Cost-effectiveness analysis
The simulation model uses information on the NHS
costs and QALYs observed during the 12 months of trial
follow-up in the initial year (year 0). All subsequent
costs and QALYs are simulated by the model as a func-
tion of QRISK2 scores using the methods described
above. Costs and outcomes were discounted at 3.5% per
year, in line with NICE recommendations.10 Cumulative
costs and QALYs were obtained for the lifetime of
cohort members by calculating probability-weighted
averages of the number of patients in each state, the
length of time patients have been in particular states,
and the costs, mortality and quality of life associated
with each state.
RESULTS
The mean age of men (women) in the trial was 67 (69),
and men comprised 80% of trial participants. Table 1
contains baseline and adjusted 12-month QRISK2
scores—higher scores indicate higher CVD risk.
Table 2 provides the results of the cost-effectiveness
analysis for different durations of intervention effect.
The longer the assumed duration of effect, the more
likely it is that the intervention is cost-effective at cost-
effectiveness thresholds conventionally employed (ie,
£20 000 per QALY). It is notable that, even if the beneﬁ-
cial effects of the intervention on CVD risk last only
1 year, the intervention is likely to be cost-effective. This
is also apparent in the cost-effectiveness acceptability
curves, where a monotonic relationship between dur-
ation of the probability of cost-effectiveness is evident
(ﬁgure 2). The corresponding cost-effectiveness planes
for each scenario illustrate this point in a different way
(ﬁgure 3). At longer durations of effect, almost all of
the 1000 simulated incremental cost/incremental pairs
are in the northeast or southeast quadrants. At shorter
durations, an increasing but still modest number of
these pairs are in the northwest or southwest quadrants.
The small QRISK2 difference between arms means
that the control and intervention groups have very
similar risk proﬁles once the assumed duration of effect
expires. The lifetime cost-effectiveness results are there-
fore inﬂuenced, especially at short durations of effect,
Table 2 Base case cost-effectiveness results for different durations of effect: per-patient average costs and effects
Modelled duration of effect
1 year 2 years 5 years
Lifetime
(permanent)
effect
Control arm NHS costs £6595 £6617 £6608 £6602
Intervention arm NHS costs £6726 £6741 £6714 £6657
Control arm QALYs 8.573 8.573 8.573 8.572
Intervention arm QALYs 8.584 8.586 8.589 8.598
Incremental costs (95% CI) £131 (£125 to 138) £124 (£118 to 130) £107 (101 to 112) £55 (49 to 61)
Incremental QALYs (95% CI) 0.011
(0.011 to 0.011)
0.013
(0.012 to 0.013)
0.016
(0.016 to 0.017)
0.026
(0.026 to 0.027)
ICER £11 776 £9886 £6477 £2091
Probability cost-effective at £20 000 threshold 0.74 0.84 0.95 0.99
Probability cost-effective at £30 000 threshold 0.87 0.93 0.99 1.00
NMB at threshold of £20 000 (95% CI) £92 (−172 to 352) £127 (−144 to 382) £223 (−153 to 468) £472 (197 to 728)
CE, cost-effectiveness; ICER, incremental cost-effectiveness ratio; NMB, net monetary benefit; QALYs, quality-adjusted life years.
Figure 2 Cost-effectiveness acceptability curves from
lifetime simulation assuming different durations of effect.
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by the inclusion of costs and QALYs observed during the
12-month period of trial follow-up. The between-arm
cost and QALY differences in the initial 12 months are
propagated forward over the remaining lifetime of trial
participants, and are more inﬂuential than the subse-
quent minor differences in costs and QALYs associated
with different levels of simulated QRISK2. Nevertheless,
the differences in QRISK2 are consequential at longer
durations of effect, since they are associated with fewer
CVD events in the intervention arm.
DISCUSSION
Cost-effectiveness over the lifetime of participants in the
Healthlines telehealth trial was estimated using a cohort
simulation model. The probability of cost-effectiveness
increased with longer durations of effect, but even with
the shortest duration of effect, the intervention was esti-
mated to be cost-effective. These results reﬂect the cost-
effectiveness analysis at 12 months: because of the small
difference in QRISK2 between arms, the QALY differ-
ence observed at the end of trial follow-up has a major
inﬂuence on lifetime cost-effectiveness.
The model is subject to a number of limitations. The
quality of the output reﬂects the assumptions and data
used to construct and populate the model. The QRISK2
algorithm is not validated for ages beyond 84, and we
made an assumption as to growth in risk for the small
number of simulated trial participants who lived to 85
and beyond.
As in all modelling exercises of this type, the results
may be sensitive to structural assumptions, such as the
number of health states modelled.11 We cannot elimin-
ate the possibility that alternative representations of clin-
ical pathways may produce different conclusions.
However, we have relied on a representation of health
states that is consistent with the QRISK2 algorithm, the
deﬁned events (eg, stroke) of which are represented as
distinct states in the model.
The model understates uncertainty associated with
QRISK2 because the variance structures underlying the
algorithm are not published or otherwise available, and
the consequence of this is to narrow CIs around net
monetary beneﬁt statistics. This may have implications,
in particular, for the probability of cost-effectiveness.
We have not accounted for non-health service costs,
which may have consequences for carers and the wider
economy for some of the conditions modelled, such as
stroke.25 However, it is not clear if accounting for these
costs would necessarily alter the between-arm compari-
son of cost-effectiveness, since slightly fewer fatal and
non-fatal strokes would be experienced in the interven-
tion arm.
Finally, the analysis does not identify the most plaus-
ible duration of effect. Evidence from long-term
follow-up is necessary to conclusively answer this ques-
tion, although synthesis of evidence from similar trials
and relevant observational studies may also offer a useful
complementary approach to long-term follow-up.
Figure 3 Cost-effectiveness planes from lifetime simulation assuming different durations of effect.
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Comparison with other literature
Comparison of the ﬁndings of this study with other lit-
erature assessing the long-term cost-effectiveness of
interventions directed at managing CVD risk is compli-
cated by differences in the study design used to inform
the modelling, patient proﬁles and the nature of the
interventions examined. However, the approach of using
different assumed durations of effect, or different effect
sizes, is encountered in similar studies.
For example, the evaluations of CVD interventions
from a long-term perspective undertaken by Mistry
et al,19 Asaria et al26 and Penaloza-Ramos et al27 are all
sensitive to some degree to assumptions made concern-
ing the duration of intervention effect. This is in spite of
differences between these studies in population
characteristics, CVD risk equation used and interven-
tions studied, which preclude a comparison of the ﬁnd-
ings of the present study and these other analyses.
Studies also differ in the study design used to inform
long-term cost-effectiveness modelling. The effect esti-
mates used as the basis of modelling in our study are those
of the ‘intention to treat’ analysis of the Healthlines RCT.
This is a source of difference between the present paper
and, for example, the economic modelling undertaken in
support of the routine use of ‘health checks’ in the NHS
in England.28 The economic model developed to analyse
the consequences of these health checks was based on a
much more extensive simulation involving synthesis of
various model parameters, compliance rates and effect
estimates from a variety of sources.
Ultimately, although modelling and evidence synthesis
will continue to be important sources of evidence in this
area, deﬁnitive evidence on the long-term consequences
for CVD risk of Healthlines (and similar interventions)
will require RCTs with long-term follow-up.
CONCLUSION
The Healthlines telehealth service is likely to be cost-
effective for individuals with raised CVD risk when a life-
time perspective is adopted. Results are somewhat sensi-
tive to the assumed duration of intervention effect.
When considering the deployment of large-scale tele-
health programmes in this area, decision makers may
need to consider the longevity of the behavioural and
other changes rendered by the type of telehealth service
studied in the Healthlines RCT, alongside other evi-
dence concerning the long-term cost-effectiveness of
similar interventions for CVD risk.
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